Community pharmacists could screen at-risk groups for liver disease

People at risk of the disease could be screened in community pharmacies that already offer needle exchange or methadone services.

Community pharmacists have the potential to screen at-risk groups for hepatitis C and could play a key role in helping to improve liver disease services in primary care, according to the conclusions of a commission set up to investigate the impact of the disease.

Writing in The Lancet (online, 27 November 2014)[1], the group of leading doctors and medical scientists who made up the commission argue that screening for hepatitis C in primary care is cost-effective.

People at risk of the disease could be screened in community pharmacies that already offer needle exchange or methadone services, suggests the group, led by Roger Williams, director of the institute of hepatology at Foundation for Liver Research, London.

Read more...


Labels: ,